Sun Pharmaceutical Q1 Results: Profit Falls 20% As Exceptional Loss Weighs
Sun Pharmaceutical Industries Ltd.’s net profit declined in the first quarter of fiscal year 2026, as the bottom-line was dragged by a one-time exceptional loss of Rs 818 crore.
India’s largest drugmaker’s consolidated net profit fell nearly 20% year-on-year to Rs 2,154 crore in the June quarter, according to an exchange filing on Thursday. That compares with the Rs 3,042-crore consensus estimate of analysts tracked by Bloomberg.
Sun Pharma Q1 FY26 Results Highlights (Consolidated, YoY)
- Revenue up 9.5% at Rs 13,851 crore vs Rs 12,653 crore (Bloomberg Estimate: Rs 13,699 crore)
- Ebitda up 11.3% at Rs 4,073 crore versus Rs 3,658 crore (Bloomberg Estimate: Rs 3,835 crore)
- Margin at 29.4% versus 28.9% (Bloomberg Estimate: 28%)
- Net profit down 19.6% at Rs 2,279 crore versus Rs 2,836 crore (Bloomberg Estimate: Rs 3,042 crore)
- India formulation sales at Rs 4721 crore, up 13.9%.
- US formulation sales at US$ 473 million, up 1.4%.
- Global innovative medicines sales at $ 311 million, up 16.9%.
- Emerging markets formulation sales at $ 298 million, up 5.1%.
- Rest of world formulation sales at $ 219 million, up 15.5%.
- R&D investments stood at Rs. 902.9 crore or 6.5% of sales.
Impact on Indian Stock Market
The Q1 results of Sun Pharmaceutical Industries Ltd. are likely to have a significant impact on the Indian stock market, particularly on the pharmaceutical sector. The company’s net profit decline may lead to a decrease in investor sentiment, which could result in a fall in the stock price.
However, the company’s revenue growth and increase in Ebitda margin may provide some support to the stock price. The investors will be closely watching the company’s future performance and any updates on the exceptional loss.
Analysis of Q1 Results
The Q1 results of Sun Pharmaceutical Industries Ltd. are a mixed bag. On one hand, the company’s revenue growth and increase in Ebitda margin are positive signs. On the other hand, the net profit decline and exceptional loss are negative factors.
The company’s India formulation sales growth of 13.9% is a positive sign, indicating that the company is performing well in the domestic market. The US formulation sales growth of 1.4% is relatively slow, which may be a concern for the company.
The global innovative medicines sales growth of 16.9% is a positive sign, indicating that the company is performing well in the innovative medicines segment. The emerging markets formulation sales growth of 5.1% is relatively slow, which may be a concern for the company.
Outlook for Sun Pharmaceutical Industries Ltd.
The outlook for Sun Pharmaceutical Industries Ltd. is uncertain. The company’s Q1 results are a mixed bag, and the net profit decline and exceptional loss are negative factors.
However, the company’s revenue growth and increase in Ebitda margin are positive signs. The investors will be closely watching the company’s future performance and any updates on the exceptional loss.
The company’s ability to grow its revenue and improve its profitability will be crucial in determining its future performance. The investors will also be watching the company’s progress in the innovative medicines segment and its ability to expand its presence in the global market.
Conclusion
In conclusion, the Q1 results of Sun Pharmaceutical Industries Ltd. are a mixed bag. The company’s revenue growth and increase in Ebitda margin are positive signs, but the net profit decline and exceptional loss are negative factors.
The investors will be closely watching the company’s future performance and any updates on the exceptional loss. The company’s ability to grow its revenue and improve its profitability will be crucial in determining its future performance.
For more information on the Indian stock market and stock market news, please visit our website. We provide daily updates on the Nifty today and Sensex news, as well as analysis and insights on the Indian stock market.